Heart Failure NYHA Class III
51
11
16
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.9%
2 terminated out of 51 trials
89.5%
+2.9% vs benchmark
6%
3 trials in Phase 3/4
35%
6 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (51)
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
SIRONA 2 Trial Heart Failure NYHA Class III
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III
Association Between the Sit-To-Stand Test and the Prognosis of Patients With Heart Failure
CardioMEMS HF System Real-World Evidence Post-Approval Study
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Cardiac Neuromodulation for Heart Failure
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
Promoting Well-being and Health in Heart Failure
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
Heart Failure Management for Patient With CIED Remotely Monitored
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
Sustaining Home Heart Failure Palliative Care in Rural Appalachia
Optimizing HFrEF Patients Using BaroStim and CardioMems
Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
SIRONA Trial Heart Failure NYHA Class III
Hemodynamic-GUIDEd Management of Heart Failure
REDUCED FUNCTIONALITY AND KINESIOPHOBIA IN PATIENTS WITH HEART FAILURE: USE OF ALTERNATIVE THERAPEUTIC STRATEGIES